{"id":15082,"date":"2026-08-11T07:31:00","date_gmt":"2026-08-11T11:31:00","guid":{"rendered":"https:\/\/cov19longhaulfoundation.org\/?p=15082"},"modified":"2026-08-11T07:34:01","modified_gmt":"2026-08-11T11:34:01","slug":"long-covid-and-persistent-pulmonary-dysfunction-emerging-evidence-for-chronic-respiratory-sequelae-pulmonary-pathology-and-dyspnea","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=15082","title":{"rendered":"Long COVID and Persistent Pulmonary Dysfunction: Emerging Evidence for Chronic Respiratory Sequelae, Pulmonary Pathology, and Dyspnea"},"content":{"rendered":"\n<p class=\"has-small-font-size wp-block-paragraph\">John Murphy,  President COVID-19 Long-haul Foundation<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Abstract<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Long COVID, also termed post-COVID condition or post-acute sequelae of SARS-CoV-2 infection (PASC), continues to represent one of the most consequential chronic disease challenges of the post-pandemic era. Although long COVID manifests as a multisystem disorder, persistent respiratory symptoms remain among its most prevalent and disabling features. Dyspnea, exercise intolerance, chest tightness, chronic cough, and impaired pulmonary function frequently persist months to years following acute infection, even among individuals who experienced mild initial illness.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Research published during 2026 has substantially refined understanding of the pulmonary manifestations of long COVID. Contemporary investigations demonstrate that persistent respiratory impairment often occurs despite relatively preserved spirometric measurements. Advanced physiologic testing, diffusion capacity assessment, quantitative imaging, ventilation-perfusion studies, transcriptomic analyses, and immunophenotyping have revealed evidence of persistent alveolar-capillary dysfunction, microvascular injury, immune dysregulation, pulmonary fibrosis, and altered respiratory physiology.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Recent studies further suggest that pulmonary manifestations of long COVID may arise from multiple overlapping mechanisms, including residual tissue injury from acute infection, chronic immune activation, endothelial dysfunction, aberrant wound healing, persistent inflammatory signaling, and impaired pulmonary vascular regulation. Emerging genomic and transcriptomic investigations have identified molecular signatures associated with pulmonary impairment, including dysregulated monocyte activation, persistent inflammatory pathway activation, and alterations in cellular repair programs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This review synthesizes recent evidence concerning the etiology, physiology, pathology, genomics, clinical progression, treatment strategies, and long-term prognosis of pulmonary dysfunction in long COVID. Collectively, available evidence supports the concept that long COVID-associated respiratory disease represents a heterogeneous but biologically identifiable syndrome characterized by persistent abnormalities involving the alveolar-capillary interface, pulmonary vasculature, and systemic immune system.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Introduction<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">The respiratory system was the primary target of acute SARS-CoV-2 infection during the initial phase of the COVID-19 pandemic. As the pandemic evolved, however, it became increasingly apparent that pulmonary consequences frequently persisted long after apparent virologic recovery.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Persistent shortness of breath remains among the most commonly reported symptoms of long COVID. In many patients, dyspnea persists despite normal chest radiography and conventional pulmonary function testing. This paradox initially challenged traditional concepts of respiratory disease and prompted investigators to pursue more sophisticated physiologic, imaging, and molecular approaches.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Studies published during 2026 have significantly advanced understanding of these persistent respiratory manifestations. Evidence increasingly indicates that long COVID-associated dyspnea cannot be explained solely by residual pulmonary scarring. Instead, pulmonary dysfunction appears to arise from complex interactions among alveolar injury, microvascular pathology, endothelial dysfunction, immune dysregulation, altered gas exchange, autonomic abnormalities, and impaired cellular repair mechanisms.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Epidemiology of Respiratory Long COVID<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Respiratory manifestations remain among the most frequently reported components of long COVID. Dyspnea, exercise intolerance, reduced aerobic capacity, and chronic cough occur across diverse patient populations and may affect individuals regardless of age, sex, or severity of initial infection.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Large observational cohorts continue to demonstrate substantial persistence of respiratory symptoms months and years following acute SARS-CoV-2 infection. Recent analyses suggest that pulmonary manifestations contribute significantly to long-term disability, healthcare utilization, and diminished quality of life among affected individuals.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Importantly, pulmonary symptoms frequently persist even when conventional diagnostic testing appears normal, suggesting that standard respiratory assessments may underestimate the true burden of disease.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Etiology<\/h4>\n\n\n\n<h5 class=\"wp-block-heading\">Residual Pulmonary Injury<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">One major etiologic mechanism involves residual tissue injury sustained during acute infection.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SARS-CoV-2 infects respiratory epithelial cells and initiates inflammatory cascades capable of producing diffuse alveolar damage, endothelial injury, microvascular thrombosis, and disruption of alveolar-capillary integrity. Although acute inflammation resolves in most individuals, evidence suggests that incomplete repair may result in persistent physiologic abnormalities.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Persistent Immune Dysregulation<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Emerging evidence increasingly implicates persistent immune activation as a driver of pulmonary symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A landmark 2026 Nature Immunology study identified a distinct monocyte transcriptional state associated with pulmonary impairment among individuals with long COVID. Investigators demonstrated that systemic immune dysregulation correlated with persistent respiratory abnormalities, supporting the hypothesis that chronic immunologic activation contributes to ongoing pulmonary dysfunction.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Persistent activation of inflammatory pathways, including interferon signaling, JAK-STAT pathways, complement activation, and cytokine-mediated responses, may perpetuate tissue injury and interfere with normal pulmonary repair processes.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Pulmonary Microvascular Disease<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Pulmonary vascular abnormalities represent another increasingly recognized contributor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Evidence from ventilation-perfusion imaging studies demonstrates persistent functional abnormalities involving pulmonary perfusion and gas exchange. These findings suggest that pulmonary symptoms may reflect microvascular dysfunction in addition to structural lung injury.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Pulmonary Physiology<\/h4>\n\n\n\n<h5 class=\"wp-block-heading\">Diffusion Impairment<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Among physiologic abnormalities identified in long COVID, impairment of diffusing capacity for carbon monoxide (DLCO) remains the most consistently reported finding.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A 2026 observational study evaluating patients with persistent respiratory symptoms found diffusion abnormalities in approximately three-quarters of affected individuals despite largely preserved spirometric indices. Investigators reported that forced expiratory volume and forced vital capacity frequently remained within normal ranges while gas-transfer abnormalities persisted.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These observations suggest that dysfunction occurs primarily at the alveolar-capillary interface rather than within conducting airways.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Ventilation-Perfusion Mismatch<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Advanced imaging studies have revealed persistent ventilation-perfusion abnormalities among patients with long COVID.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Registry data utilizing V\/Q SPECT\/CT imaging demonstrated functional alterations that frequently persisted after apparent clinical recovery. Such abnormalities may contribute directly to dyspnea, exertional intolerance, and reduced exercise capacity.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Exercise Physiology<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Cardiopulmonary exercise testing has revealed impaired oxygen extraction, reduced peak aerobic capacity, and abnormal ventilatory responses in subsets of long COVID patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These findings support the concept that pulmonary symptoms reflect integrated dysfunction involving respiratory, vascular, and metabolic systems rather than isolated airway disease.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Pulmonary Pathology<\/h4>\n\n\n\n<h5 class=\"wp-block-heading\">Ground-Glass Opacities<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Ground-glass opacities remain among the most common radiographic findings reported in long COVID cohorts.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Recent investigations identified persistent ground-glass abnormalities in approximately two-thirds of symptomatic patients undergoing CT evaluation. These findings may reflect ongoing inflammation, incomplete alveolar repair, or persistent interstitial abnormalities.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Fibrotic Change<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Fibrotic remodeling represents a major concern regarding long-term pulmonary outcomes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The 2026 Biomedicines study reported fibrotic changes in more than half of symptomatic long COVID patients undergoing CT evaluation. Fibrotic alterations may contribute to restrictive physiology, impaired gas exchange, and persistent exertional dyspnea.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Air Trapping and Small Airways Disease<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Increasing evidence suggests involvement of distal airways.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Investigators have reported air trapping, bronchial wall thickening, and evidence of small airways dysfunction among symptomatic patients. These findings may not be adequately captured by conventional spirometry.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Genomics and Molecular Mechanisms<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Recent genomic and transcriptomic investigations have identified biological signatures associated with pulmonary impairment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Nature Immunology study demonstrated distinct transcriptional profiles among circulating monocytes that correlated with pulmonary dysfunction. Genes involved in inflammatory regulation, antigen presentation, immune signaling, and cellular activation appeared differentially expressed among affected individuals.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Additional investigations have implicated persistent activation of interferon pathways, complement cascades, inflammatory cytokine signaling, and immune exhaustion programs. These molecular findings support a biologically active disease process rather than a static residual injury state.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Clinical Progression<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Longitudinal investigations reveal substantial heterogeneity in disease trajectories.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Some patients demonstrate gradual improvement over time, while others experience persistent symptoms extending several years beyond initial infection. Recent computational phenotyping analyses have identified multiple distinct clinical trajectories, including recovery, partial-response, and refractory phenotypes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pulmonary symptoms often fluctuate and may worsen following physical exertion, respiratory infections, or periods of physiologic stress.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Therapeutic Management<\/h4>\n\n\n\n<h5 class=\"wp-block-heading\">Pulmonary Rehabilitation<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Pulmonary rehabilitation remains among the most widely utilized interventions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Structured rehabilitation programs may improve exercise tolerance, respiratory muscle performance, functional capacity, and quality of life. Current evidence supports individualized rehabilitation approaches tailored to symptom severity and exercise tolerance.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Breathing Retraining<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Breathing retraining techniques have demonstrated benefit in selected patients exhibiting dysfunctional breathing patterns, hyperventilation syndromes, or autonomic abnormalities.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Pharmacologic Therapy<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">At present, no pharmacologic treatment has received universal acceptance specifically for long COVID pulmonary disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Investigational approaches include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Anti-inflammatory therapies<\/li>\n\n\n\n<li>Antifibrotic agents<\/li>\n\n\n\n<li>Endothelial-directed therapies<\/li>\n\n\n\n<li>Immune-modulating interventions<\/li>\n\n\n\n<li>Antiviral strategies<\/li>\n\n\n\n<li>Targeted biologic therapies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Robust randomized controlled trial data remain limited.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Long-Term Prognosis<\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">Long-term prognosis remains incompletely defined.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Available evidence suggests that pulmonary function generally improves over time in many patients, particularly during the first one to two years after infection. Nevertheless, a substantial proportion continue to demonstrate physiologic impairment, radiographic abnormalities, and persistent respiratory symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current evidence indicates that recovery is possible but often prolonged. Persistent diffusion abnormalities, fibrotic changes, and microvascular dysfunction may contribute to ongoing symptoms in susceptible individuals. Continued surveillance and longitudinal cohort studies remain essential to define ultimate pulmonary outcomes.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">References<\/h5>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li>Daodu LP, et al. Biomedicines. 2026;14(1):145.<\/li>\n\n\n\n<li>Kumar S, et al. Nature Immunology. 2026.<\/li>\n\n\n\n<li>Bonnefoy PB, et al. Eur J Nucl Med Mol Imaging. 2026.<\/li>\n\n\n\n<li>Li S, et al. Respiratory Research. 2026.<\/li>\n\n\n\n<li>Prospective analysis of post-COVID-19 hospitalization: Clinics. 2026.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>John Murphy, President COVID-19 Long-haul Foundation Abstract Long COVID, also termed post-COVID condition or post-acute sequelae of SARS-CoV-2 infection (PASC), continues to represent one of the most consequential chronic disease [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":15579,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[663,990,293,1035,1292,929,492,592],"tags":[],"class_list":["post-15082","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-acute-respiratory-distress","category-dyspnea","category-lung-disease","category-pathophysiology","category-pulmonary-rehabilitation","category-respiration","category-respiratory-syndrome","category-treatments"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15082"}],"version-history":[{"count":4,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15082\/revisions"}],"predecessor-version":[{"id":15578,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15082\/revisions\/15578"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/15579"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}